Publications by authors named "Benn Falch Sejergaard"
Aim: An objective assessment of small nerve fibers is key to the early detection of diabetic peripheral neuropathy (DPN). This study investigates the diagnostic accuracy of a novel perception threshold tracking technique in detecting small nerve fiber damage.
Methods: Participants with type 1 diabetes (T1DM) without DPN (n = 20), with DPN (n = 20), with painful DPN (n = 20) and 20 healthy controls (HCs) underwent perception threshold tracking on the foot and corneal confocal microscopy.
Article Synopsis
- * In a study involving six minipigs, researchers induced CRVO and treated one eye with a DEX implant while using a sham injection in the other eye, allowing them to compare the effects.
- * Results showed that DEX treatment led to increased levels of the protein FKBP5 in the retina, suggesting ongoing activity of the drug, while several other proteins were downregulated, highlighting potential mechanisms behind DEX's beneficial effects.
Aflibercept is a frequently used inhibitor of vascular endothelial growth factor (VEGF) in the treatment of macular edema following central retinal vein occlusion (CRVO). Retinal proteome changes following aflibercept intervention in CRVO remain largely unstudied. Studying proteomic changes of aflibercept intervention may generate a better understanding of mechanisms of action and uncover aspects related to the safety profile.
View Article and Find Full Text PDFAflibercept is an inhibitor of vascular endothelial growth factor (VEGF) used to treat macular edema following branch retinal vein occlusion (BRVO). Despite well-documented efficacy, there is limited knowledge about proteome changes following aflibercept intervention in BRVO. Proteome changes may provide insights into mechanisms of action as well as aspects related to safety profile.
View Article and Find Full Text PDF